Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

Ítems similars

• 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
  per: van der Heijde, Désirée, et al.
  Publicat: (2018)
• Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
  per: Mease, P J, et al.
  Publicat: (2014)
• Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
  per: van der Heijde, D, et al.
  Publicat: (2014)
• Correction to: Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
  per: Dattola, Annunziata, et al.
  Publicat: (2017)
• EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
  per: T. V. Korotaeva, et al.
  Publicat: (2015-10-01)